Auris Medical Holding AG (NASDAQ:EARS) saw a large increase in short interest during the month of April. As of April 28th, there was short interest totalling 1,075,288 shares, an increase of 15.4% from the April 13th total of 932,128 shares. Based on an average daily trading volume, of 174,449 shares, the days-to-cover ratio is currently 6.2 days.
Auris Medical Holding AG (NASDAQ:EARS) traded down 0.620% during mid-day trading on Tuesday, hitting $0.641. 200,403 shares of the stock were exchanged. The stock’s market cap is $28.41 million. Auris Medical Holding AG has a 52 week low of $0.60 and a 52 week high of $5.45. The company has a 50 day moving average price of $0.67 and a 200 day moving average price of $0.92.
Auris Medical Holding AG (NASDAQ:EARS) last released its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.08. Analysts expect that Auris Medical Holding AG will post ($0.72) EPS for the current fiscal year.
A number of equities analysts have commented on EARS shares. Needham & Company LLC cut their price objective on shares of Auris Medical Holding AG from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, March 14th. Roth Capital assumed coverage on shares of Auris Medical Holding AG in a report on Thursday, April 13th. They issued a “buy” rating and a $4.50 price target for the company. Finally, ValuEngine downgraded shares of Auris Medical Holding AG from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $3.25.
A number of institutional investors have recently made changes to their positions in the stock. Sabby Management LLC bought a new position in shares of Auris Medical Holding AG during the first quarter valued at $133,000. Morgan Stanley boosted its position in Auris Medical Holding AG by 37,537.6% in the first quarter. Morgan Stanley now owns 150,174 shares of the biotechnology company’s stock worth $138,000 after buying an additional 149,775 shares during the period. Perceptive Advisors LLC acquired a new position in Auris Medical Holding AG during the first quarter worth approximately $368,000. UBS Oconnor LLC acquired a new position in Auris Medical Holding AG during the first quarter worth approximately $909,000. Finally, Sofinnova Management VIII L.L.C. boosted its position in Auris Medical Holding AG by 34.4% in the first quarter. Sofinnova Management VIII L.L.C. now owns 7,818,175 shares of the biotechnology company’s stock worth $7,193,000 after buying an additional 2,000,000 shares during the period. 29.06% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thestockobserver.com/2017/06/20/short-interest-in-auris-medical-holding-ag-ears-increases-by-15-4-updated-updated-updated-updated.html.
About Auris Medical Holding AG
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.
Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.